Skip to main content

Table 1 Difference in baseline clinical and angiographic characteristics among the MACE and non-MACE group of study population (total population)

From: The atherogenic index of plasma plays an important role in predicting the prognosis of type 2 diabetic subjects undergoing percutaneous coronary intervention: results from an observational cohort study in China

Characteristics

MACE (n = 483)

Non-MACE (n = 1873)

P value

Demographic

 Age, years

58.03 ± 9.039

57.95 ± 9.182

0.867

 Male, n (%)

353 (73.1)

1385 (73.9)

0.701

Behavioral

 Smoking, n (%)

215 (44.5)

832 (44.4)

0.971

 Drinking, n (%)

85 (17.6)

331 (17.7)

0.97

Physical

 BMI, kg/m2

26.07 ± 3.564

26.07 ± 3.504

0.985

 SBP, mmHg

129.64 ± 14.982

130.5 ± 16.485

0.27

 DBP, mmHg

77.67 ± 9.913

77.8 ± 10.614

0.81

Medical history, n (%)

 Hypertension

299 (61.9)

1208 (64.5)

0.29

 Hyperlipidemia

209 (43.3)

812 (43.4)

0.974

 History of MI

50 (10.4)

201 (10.7)

0.81

 History of stroke

29 (6.0)

144 (7.7)

0.206

 Family history of CAD

62 (12.8)

260 (13.9)

0.551

 Previous PCI

79 (16.4)

317 (16.9)

0.766

 Diagnosed DM, years

7.82 ± 3.73

6.58 ± 3.942

< 0.001

Clinical presentation, n (%)

 Stable CAD

52 (10.8)

249 (13.3)

0.138

 Unstable angina/NSTEMI

352 (72.9)

1267 (67.6)

0.027

 STEMI

79 (16.3)

357 (19.1)

0.172

Medical treatment, n (%)

 Asprin

479 (99.2)

1862 (99.4)

0.785

 Clopidogrel

476 (98)

1832 (97.8)

0.305

 β-Blocker

391 (81)

1498 (80)

0.632

 Statins

473 (97.9)

1827 (97.5)

0.62

 ACEI/ARB

275 (56.9)

1028 (54.9)

0.419

 Oral hypoglycemic drugs

353 (72.9)

1322 (70.6)

0.321

 Insulin

183 (37.9)

649 (34.7)

0.184

Laboratory results

 TC, mmol/L

4.25 ± 1.111

4.11 ± 1.091

0.015

 LDL-C, mmol/L

2.49 ± 0.841

2.47 ± 0.89

0.643

 AIP

0.3 ± 0.356

0.22 ± 0.292

< 0.001

 HbA1c, %

8.1 ± 1.269

7.4 ± 1.299

< 0.001

 hs-CRP, mg/L

4.18 ± 6.708

4.01 ± 6.877

0.614

 Creatinine, μmol/L

71.98 ± 17.595

71.46 ± 19.905

0.604

 GFR, mL/min

95.13 ± 20.680

95.79 ± 19.612

0.515

 LVEF, %

61.44 ± 8.231

62.09 ± 8.15

0.118

Number of target vessels

0.229

 One, n (%)

206 (45.1)

856 (45.7)

 

 Multivessel, n (%)

277 (57.3)

1017 (54.3)

 

Target vessels

 LM, n (%)

17 (3.5)

75 (4)

0.624

 LAD, n (%)

290 (60)

1121 (59.9)

0.939

 LCX, n (%)

720 (34.8)

200 (41.4)

0.233

 RCA, n (%)

212 (43.9)

782 (41.8)

0.396

 SYNTAX score

14.61 ± 6.971

12.48 ± 7.162

< 0.001

 Minimal stent diameter, mm

2.92 ± 0.457

2.92 ± 0.46

0.931

 Average stent length, mm

22.27 ± 6.748

22.16 ± 6.43

0.749

Types of stent, n (%)

0.338

 First generation DES

225 (46.6)

827 (44.2)

 

 Second generation DES

258 (53.4)

1046 (55.8)

 
  1. Continuous variables were expressed as mean (\({\bar{\text{x}}}\)) ± standard deviation (SD) in case of normal distribution and compared between two groups by two-independent samples t-test. Data were expressed as medians (interquartile ranges) in case of skewed distribution and compared using the Mann–Whitney U-test. Categorical variables are presented as counts (percentages) and compared by Chi-square test
  2. MACCE major adverse cardiac and cerebrovascular event, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, DM diabetes mellitus, MI myocardial infraction, CAD coronary artery disease, PCI percutaneous coronary intervention, NSTEMI non-ST-segment–elevation myocardial infarction, STEMI ST-segment–elevation myocardial infarction, TG triglyceride, TC total cholesterol, LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, AIP atherogenic index of plasma, HbA1c glycosylated hemoglobin, hs-CRP high-sensitivity C-reactive protein, LVEF left ventricular ejection fraction, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, LM left main, LAD left anterior descending, LCX left circumflex artery, RCA right coronary artery, SYNTAX synergy between PCI with taxus and cardiac surgery, DES drug-eluting stent